BBT-207
- Generic Name
- BBT-207
First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI
Phase 1
Active, not recruiting
- Conditions
- EGFR Mutant Advanced Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Bridge Biotherapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05920135
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath